: In this commentary, we discuss the investigation into reports of T-cell malignancies following chimeric antigen receptor T-cell therapy. We argue that although these cases should be thoroughly examined, current data suggest that such risks with autologous chimeric antigen receptor T cells are remarkably low compared with other cancer treatments. We also emphasize the importance of continued research, transparent reporting, and participation in postauthorization safety studies.
CAR T-cell Resistance to Oncogenic Transformation
Ruella, Marco;
2024-01-01
Abstract
: In this commentary, we discuss the investigation into reports of T-cell malignancies following chimeric antigen receptor T-cell therapy. We argue that although these cases should be thoroughly examined, current data suggest that such risks with autologous chimeric antigen receptor T cells are remarkably low compared with other cancer treatments. We also emphasize the importance of continued research, transparent reporting, and participation in postauthorization safety studies.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
bcd-23-0273.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
4.98 MB
Formato
Adobe PDF
|
4.98 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
